Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. more
Time Frame | KZIA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.29% | -3.32% | 0.62% |
1-Month Return | -33.07% | -1.85% | 3.15% |
3-Month Return | 6.18% | -10.48% | 7.77% |
6-Month Return | 47.83% | -4.41% | 10.91% |
1-Year Return | -15% | 4.13% | 28.07% |
3-Year Return | -95.53% | 1.01% | 31.43% |
5-Year Return | -92% | 36.77% | 90.01% |
10-Year Return | -97.29% | 103.02% | 201.22% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.06K | 15.18M | 25.00 | 555.00 | 2.31M | [{"date":"2020-06-30","value":0.01,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":15.2,"profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Gross Profit | 1.06K | 15.18M | 25.00 | 555.00 | 2.31M | [{"date":"2020-06-30","value":0.01,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":15.2,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Operating Expenses | 13.16M | 24.13M | 24.88M | 24.12M | 2.31M | [{"date":"2020-06-30","value":52.9,"profit":true},{"date":"2021-06-30","value":96.99,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":96.96,"profit":true},{"date":"2024-06-30","value":9.28,"profit":true}] |
Operating Income | (12.53M) | (6.38M) | (26.70M) | (24.12M) | - | [{"date":"2020-06-30","value":-1252500000,"profit":false},{"date":"2021-06-30","value":-637828600,"profit":false},{"date":"2022-06-30","value":-2669632700,"profit":false},{"date":"2023-06-30","value":-2412396900,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Total Non-Operating Income/Expense | (503.58K) | (2.48M) | 1.68M | 3.41M | - | [{"date":"2020-06-30","value":-14.77,"profit":false},{"date":"2021-06-30","value":-72.83,"profit":false},{"date":"2022-06-30","value":49.34,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Pre-Tax Income | (12.77M) | (8.91M) | (25.02M) | (20.74M) | (27.05M) | [{"date":"2020-06-30","value":-1276500000,"profit":false},{"date":"2021-06-30","value":-890630700,"profit":false},{"date":"2022-06-30","value":-2501589500,"profit":false},{"date":"2023-06-30","value":-2073627200,"profit":false},{"date":"2024-06-30","value":-2704900000,"profit":false}] |
Income Taxes | (298.00K) | 484.35K | (368.08K) | 271.09K | (271.00K) | [{"date":"2020-06-30","value":-61.53,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-76,"profit":false},{"date":"2023-06-30","value":55.97,"profit":true},{"date":"2024-06-30","value":-55.95,"profit":false}] |
Income After Taxes | (12.47M) | (9.39M) | (24.65M) | (21.01M) | - | [{"date":"2020-06-30","value":-1246700000,"profit":false},{"date":"2021-06-30","value":-939065400,"profit":false},{"date":"2022-06-30","value":-2464781500,"profit":false},{"date":"2023-06-30","value":-2100736400,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Continuous Operations | (12.47M) | (8.42M) | (24.65M) | (20.47M) | - | [{"date":"2020-06-30","value":-1246700000,"profit":false},{"date":"2021-06-30","value":-842200000,"profit":false},{"date":"2022-06-30","value":-2464781500,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (12.47M) | (8.42M) | (24.65M) | (20.47M) | (26.78M) | [{"date":"2020-06-30","value":-1246700000,"profit":false},{"date":"2021-06-30","value":-842196000,"profit":false},{"date":"2022-06-30","value":-2464781500,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":-2677800000,"profit":false}] |
EPS (Diluted) | (0.11) | - | - | - | - | [{"date":"2020-06-30","value":-10.6,"profit":false},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
KZIA | |
---|---|
Cash Ratio | 0.06 |
Current Ratio | 0.24 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KZIA | |
---|---|
ROA (LTM) | -46.42% |
ROE (LTM) | -186.37% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KZIA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.46 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.46 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KZIA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 26440.83 |
P/B | 3.09 |
Price/FCF | NM |
EV/R | 9.62 |
EV/Ebitda | NM |
Kazia Therapeutics Ltd ADR (KZIA) share price today is $3.4
Yes, Indians can buy shares of Kazia Therapeutics Ltd ADR (KZIA) on Vested. To buy Kazia Therapeutics Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KZIA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Kazia Therapeutics Ltd ADR (KZIA) via the Vested app. You can start investing in Kazia Therapeutics Ltd ADR (KZIA) with a minimum investment of $1.
You can invest in shares of Kazia Therapeutics Ltd ADR (KZIA) via Vested in three simple steps:
The 52-week high price of Kazia Therapeutics Ltd ADR (KZIA) is $15.8. The 52-week low price of Kazia Therapeutics Ltd ADR (KZIA) is $1.87.
The price-to-earnings (P/E) ratio of Kazia Therapeutics Ltd ADR (KZIA) is
The price-to-book (P/B) ratio of Kazia Therapeutics Ltd ADR (KZIA) is 3.09
The dividend yield of Kazia Therapeutics Ltd ADR (KZIA) is 0.00%
The market capitalization of Kazia Therapeutics Ltd ADR (KZIA) is $15.46M
The stock symbol (or ticker) of Kazia Therapeutics Ltd ADR is KZIA